Facet Life Sciences and XCancer Form Strategic Partnership to Accelerate Theranostic Drug Development
核心洞察
Facet Life Sciences (搜索) has partnered with XCancer (搜索) to combine regulatory expertise with clinical trial infrastructure to accelerate radiopharmaceutical therapy development in oncology.
The collaboration integrates Facet's FDA submission and regulatory strategy capabilities with XCancer (搜索)'s extensive theranostic clinical trial network through the TheranosticTrials.Org platform.
The partnership aims to streamline complex development pathways for next-generation radiopharmaceutical therapies that combine diagnostic imaging with targeted cancer treatment.
Facet Life Sciences (搜索), a regulatory strategy and drug development services company, has announced a strategic partnership with XCancer (搜索), a global leader in theranostic clinical research, to accelerate the development and approval of next-generation radiopharmaceutical therapies in oncology. The collaboration aims to streamline the complex regulatory pathways that often delay innovative cancer treatments from reaching patients.
Partnership Structure and Platform Integration
As part of the alliance, Facet is now featured on TheranosticTrials.Org, XCancer (搜索)'s premier collaboration platform that connects researchers, clinicians, sponsors, and advocates to expand awareness, share expertise, and promote global access to cancer innovation. The platform serves as a global hub designed to foster collaboration and advance the reach of innovative cancer treatments.
The partnership combines Facet's deep regulatory and development expertise in diagnostic and therapeutic radiopharmaceuticals—including U.S. regulatory planning, FDA submissions, and oncology program strategy—with XCancer (搜索)'s expansive theranostic clinical trial network and infrastructure.
Leadership Perspectives on Collaboration Impact
"At Facet, our mission has always included bringing diagnostic and radiopharmaceutical therapies to patients faster and more efficiently," said Dr. Lisa Jenkins VanLuvanee, COO of Facet Life Sciences (搜索). "By partnering with XCancer (搜索) and TheranosticTrials.Org, we are combining our regulatory and oncology expertise with their groundbreaking clinical research capabilities. This collaboration positions us to accelerate the advancement of theranostic therapies and expand patient access to precision medicine."
Dr. Luke Nordquist, CEO of XCancer (搜索) and Founder of TheranosticTrials.Org, emphasized the complementary nature of the partnership. "Facet's proven regulatory and strategic development expertise complements XCancer's mission perfectly," he said. "Together, we are building an ecosystem that removes barriers for Sponsors, accelerates clinical trial activation, and brings life-changing radiopharmaceutical therapies to patients who need them most. This partnership exemplifies what theranostics is all about—uniting diagnostics and therapeutics through collaboration to deliver truly personalized cancer care."
Clinical Research Infrastructure and Capabilities
XCancer (搜索) operates one of the nation's largest community-based research networks, conducting hundreds of Phase I–III clinical trials, including more than 20 first-in-world studies in radiopharmaceuticals and precision oncology. The organization's mission focuses on expanding access to cancer innovations by partnering with sponsors, community cancer centers, and research collaborators worldwide.
The collaboration represents a strategic approach to addressing the growing trend in oncology of integrating diagnostic imaging with targeted therapy, known as theranostics. This approach represents one of the most promising frontiers in oncology, combining diagnostic imaging with targeted therapy to achieve truly personalized cancer care.
Regulatory and Development Focus
Facet Life Sciences (搜索) brings specialized expertise in regulatory strategy, drug development planning, U.S. regulatory submissions, strategic statistics, and commercialization support. The employee-owned company has established a strong focus on diagnostic and theranostic pharmaceuticals, oncology, and rare disease programs.
The partnership will simplify the complex development and regulatory pathways that often delay innovative therapies from reaching patients in need. Together, the organizations will streamline the path for sponsors to bring precision diagnostic and therapeutic radiopharmaceuticals to patients more efficiently.
Theranostic Innovation Ecosystem
TheranosticTrials.Org serves as a global platform dedicated to advancing collaboration, awareness, access, and education in theranostics. The platform connects researchers, clinicians, sponsors, industry partners, patients, and advocates to share expertise, promote clinical trial visibility, and expand global access to radiopharmaceutical innovation.
The platform accelerates the growth of the theranostic ecosystem by highlighting capabilities, fostering partnerships, and supporting equitable access to life-changing cancer treatments. XCancer (搜索) empowers sites to deliver world-class care close to home through its extensive network and collaborative approach.